How Pharmeasy Lost 90% value in three years?

0:00 Intro 1:15 Origin Story 4:43 Scaling up 7:20 Cracks Emerging 10:40 Lessons 12:12 Future Uncertainty PharmEasy's Rise and Fall PharmEasy started with a vision to simplify India’s fragmented medicine market, growing quickly and acquiring Thyrocare in a historic deal. By 2021, it was India’s first health-tech unicorn with a $5.6 billion valuation. However, its aggressive expansion, high debt from acquisitions, and failed IPO led to massive financial strain. As PharmEasy faced mounting losses, its valuation plunged by over 90%. Despite its past success, the company struggled to maintain momentum in a highly competitive market. Can it bounce back, or will it be acquired by bigger players like Reliance or Tata? Disclaimer: Zero1 by Zerodha financially supports creators and storytellers through its network. The views and opinions in this video are solely those of the creator and are not endorsed by Zero1. Connect with us: Twitter:   / bwmillionaires   Instagram:   / backstagewithmillionaires   Podcast: https://open.spotify.com/show/5rGPalo...